Abstract
This article seeks to deepen the understanding of sustained competitive advantages built through strategies of R&D investments, and patents and trademarks registrations by Big Pharma, within the framework of the three main activity clusters related to dynamic capabilities: sensing, seizing, and transforming. The use of this framework contributes to the comprehension of the strategies of R&D, patents, and trademarks by Big Pharma in creating sustained competitive advantages and in the endurance and stability of these companies as industry leaders. The identification of R&D opportunities emerging from the public sector, the ability to leverage identified opportunities through organizational competencies and consistent strategies for resource transformation – such as evergreening –, and brand building have been recognized as significant components of the dynamic capabilities of the firms that enable the creation and maintenance of sustained competitive advantages.
References
ABBAS, M. Z. Evergreening of pharmaceutical patents: a blithe disregard for the rationale of the patent system. Journal of Generic Medicines, London, v. 15, n. 2, p. 53-60, 2019.
ALVES, F. C.; BOMTEMPO, J. V.; COUTINHO, P. L. A. Competências para Inovar na Indústria Petroquímica Brasileira. Revista Brasileira de Inovação, Campinas, v. 4, n. 2, p. 301-327, 2009.
AL-ZAWAHREH, A.; MAHMOUD, A. R.; ALKHAWALDEH, A. M. The impact of corporate social responsibility on the performance of pharmaceutical companies in Jordan. International Journal of Business and Social Science, New York, v. 9, n. 12, p. 41-47, 2018.
AMAYA, N. et al. Role of internal resources on the competitive advantage building in a knowledge-intensive organisation in an emerging market. VINE Journal of Information and Knowledge Management Systems, Bingley, 2022. No prelo.
AMOROSO, S. et al. World corporate top R&D investors: paving the way to climate neutrality. Luxembourg: Publications Office of the European Union, 2021. Disponível em: <https://data.europa.eu/doi/10.2760/49552>. Acesso em: 22 jun. 2023.
ANGELL, M. The truth about the drug companies: how they deceive us and what to do about it. New York: Random House, 2005.
BARNEY, J. B.; MACKEY, T. B. Testing resource-based theory. Research Methodology in Strategy and Management, Bingley, v. 2, p. 1-13, 2005.
BARNEY, J. B.; MACKEY, A. Monopoly profits, efficiency profits, and teaching strategic management. Academy of Management Learning & Education, Briarcliff Manor, v. 17, n. 3, p. 359-373, 2018.
BARNEY, J. B.; KETCHEN, D. J.; WRIGHT, M. Resource-based theory and the value creation framework. Journal of Management, Thousand Oaks, v. 47, n. 7, p. 1936-1955, 2021.
BLACKETT, T.; HARRISON, T. Brand medicine: use and future potential of branding in pharmaceutical markets. International Journal of Medical Marketing, Thousand Oaks, v. 2, n. 1, p. 33-49, 2001.
BRANDENBURGER, A.; STUART, H. Value-based business strategy. Journal of Economics & Management Strategy, Cambridge, v. 5, n. 1, p. 5-24, 1996.
BUSFIELD, J. Globalization and the pharmaceutical industry revisited. International Journal of Health Services, Connecticut, v. 33, n. 3, p. 581-605, 2003.
CARRICK, J. From Penrose to complementary assets: the evolution of the resource-based literature. Journal of Management Policy and Practice, Florida, v. 14, n. 3, p. 125-156, 2013.
CHANG, J. et al. Prescription to over-the-counter switches in the United States. Journal of Management Policy and Practice, Florida, v. 5, n. 3, p. 149-154, 2016.
CHUDNOVSKY, D. Patents and trademarks in pharmaceuticals. World Development, New York, v. 11, n. 3, p. 187-193, 1983.
CLEARY, E. et al. Contribution of NIH funding to new drug approvals 2010-2016. Proceedings of the National Academy of Sciences, Washington, v. 115, n. 10, p. 2329-2334, 2018.
COMANOR, W. S.; SCHERER, F. M. Mergers and innovation in the pharmaceutical industry. Journal of Health Economics, Amsterdam, v. 32, n. 1, p. 106-113, 2013.
DE STEFANO, M. C.; MONTES-SANCHO, M. J.; BUSCH, T. A natural resource-based view of climate change: Innovation challenges in the automobile industry. Journal of Cleaner Production, Karlsruhe, v. 139, p. 1436-1448, 2016.
DIMASI, J. A.; GRABOWSKI, H. G.; HANSEN, R. W. Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, Rotterdam, v. 47, p. 20-33, 2016.
DOSI, G. et al. Big Pharma and monopoly capitalism: a long-term view. Structural Change and Economic Dynamics, Oxford, v. 65, p. 15-35, 2023.
DUARTE ALONSO, A. Exploring a developing tourism industry: a resource-based view approach. Tourism Recreation Research, Abingdon, v. 42, n. 1, p. 45-58, 2017.
EISENHARDT, K. M.; MARTIN, J. A. Dynamic capabilities: what are they? Strategic Management Journal, Chichester, v. 21, n. 10-11, p. 1105-1121, 2000. Disponível em: <https://data.europa.eu/doi/10.2760/49552>. Acesso em: 22 jun. 2023.
FELDMAN, R. May your drug price be evergreen. Journal of Law and the Biosciences, Oxford, v. 5, n. 3, p. 590-647, 2018.
GANUZA, J.-J.; LLOBET, G.; DOMÍNGUEZ, B. R&D in the pharmaceutical industry: A world of small innovations. Management Science, Maryland, v. 55, n. 4, p. 539-551, 2009.
GAUTAM, A.; PAN, X. The changing model of big pharma: impact of key trends. Drug Discovery Today, Kidlington, v. 21, n. 3, p. 379-384, 2016.
HENDERSON, R.; COCKBURN, I. Measuring competence? Exploring firm effects in pharmaceutical research. Strategic Management Journal, Chichester, v. 15, n. S1, p. 63-84, 1994.
HOLDFORD, D. A. Resource-based theory of competitive advantage: a framework for pharmacy practice innovation research. Pharmacy Practice, Colômbia, v. 16, n. 3, p. 1351, 2018.
HOSSAIN, M. S. et al. Determinants of sustainable competitive advantage from resource-based view: implications for hotel industry. Journal of Hospitality and Tourism Insights, Bingley, v. 5, n. 1, p. 79-98, 2022.
JAMES, A. D. The strategic management of mergers and acquisitions in the pharmaceutical industry: developing a resource-based perspective. Technology Analysis & Strategic Management, Abingdon, v. 14, n. 3, p. 299-313, 2002.
KAYO, E. et al. Ativos intangíveis, ciclo de vida e criação de valor. Revista de Administração Contemporânea, São Paulo, v. 10, n. 3, p. 73-90, 2006.
KESSELHEIM, A. S. An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences: review of legislation affecting drug development. Milbank Quarterly, New York, v. 89, n. 3, p. 450-502, 2011.
KNOTT, A. M.; BRYCE, D. J.; POSEN, H. E. On the strategic accumulation of intangible assets. Organization Science, Providence, v. 14, n. 2, p. 192-207, 2003.
LADHA, Z. Marketing strategy: are consumers really influenced by brands when purchasing pharmaceutical products? Journal of Medical Marketing, Thousand Oaks, v. 7, n. 2, p. 146-151, 2007.
LAZONICK, W.; MAZZUCATO, M. The risk-reward nexus in the innovation-inequality relationship: who takes the risks? Who gets the rewards? Industrial and Corporate Change, Oxford, v. 22, n. 4, p. 1093-1128, 2013.
MALERBA, F.; ORSENIGO, L. The evolution of the pharmaceutical industry. Business History, London, v. 57, n. 5, p. 664-687, 2015.
MAZZUCATO, M. The entrepreneurial state: debunking public vs. private sector myths. London: Anthem Press, 2013.
MAZZUCATO, M. The value of everything: making and taking in the global economy. London: Penguin, 2018.
MAZZUCATO, M.; ROY, V. Rethinking value in health innovation: from mystifications towards prescriptions. Journal of Economic Policy Reform, Reino Unido, v. 22, n. 2, p. 101-119, 2019.
MERCADANTE, E.; PARANHOS, J. Pharmaceutical patent term extension and patent prosecution in Brazil (1997-2018). Cadernos de Saúde Pública, Rio de Janeiro, v. 38, n. 1, p. 1-13, 2022.
PARANHOS, J.; MERCADANTE, E.; HASENCLEVER, L. Os esforços inovativos das grandes empresas farmacêuticas no Brasil. Revista Brasileira de Inovação, Campinas, v. 19, e0200015, 2020.
PENROSE, E. The theory of the growth of the firm. Oxford: Oxford University Press, 1959.
PENROSE, E. Foreign investment and the growth of the firm. The Economic Journal, Nashville, v. 45, n. 2, p. 531-543, 1995.
PENROSE, E. Limits to the growth and size of firms. The American Economic Review, Rio de Janeiro, v. 38, n. 1, p. 1-13, 2022.
PETERAF, M. A. The cornerstones of competitive advantage: a resource-based view. Strategic Management Journal, Chichester, v. 14, n. 3, p. 179-191, 1993.
PROGOULAKI, M.; THEOTOKAS, I. Human resource management and competitive advantage: an application of resource-based view in the shipping industry. Marine Policy, Amsterdam, v. 34, n. 3, p. 575-582, 2010.
SAMPAT, B. N.; LICHTENBERG, F. R. What are the respective roles of the public and private sectors in pharmaceutical innovation? Health Affairs, Millwood, v. 30, n. 2, p. 332-339, 2011.
SANTOS, T. The impact of RBV on value creation in the pharmaceutical industry. 2023. (Dissertação Mestrado) - Instituto Universitário de Lisboa, Lisboa, 2023.
SCHERER, F. M. Pharmaceutical Innovation. In: HALL, B. H.; ROSENBERG, N. (Org.). Handbook of the economics of innovation. Amsterdam: Elsevier, 2010. v. 1, p. 539-574.
SIMARMATA, M.; SINAGA, S. S.; MUDA, I. The management company intangible assets governance in pharmaceutical industry. Journal of Pharmaceutical Negative Results, Mumbai, v. 13, n. 3, p. 1628-1630, 2022.
TEECE, D. J. Explicating dynamic capabilities: the nature and microfoundations of (sustainable) enterprise performance. Strategic Management Journal, Chichester, v. 28, n. 13, p. 1319-1350, 2007.
TEECE, D. J. Technological innovation and the theory of the firm. In: HALL, B. H.; ROSENBERG, N. (Org.). Handbook of the economics of innovation. Amsterdam: Elsevier, 2010. v. 1, p. 679-730.
TEECE, D. J. Towards a capability theory of (innovating) firms: implications for management and policy. Cambridge Journal of Economics, Oxford, v. 41, n. 3, p. 693-720, 2017.
TEECE, D. J.; PISANO, G.; SHUEN, A. Dynamic capabilities and strategic management. Strategic Management Journal, Chichester, v. 18, n. 7, p. 509-533, 1997.
TOMA, S. G.; STEFAN, C. Big Pharma, big business. Strategic Management Journal, Chichester, v. 18, n. 7, p. 509-533, 1997.
WERNERFELT, B. A resource-based view of the firm. “Ovidius” University Annals, Economic Sciences Series, Constanta, v. 21, n. 1, p. 677-683, 2021.
WIBOWO, A.; HANDIKA, R. F. The strategy of the banking industry in Indonesia: following institutional theory or resource-based view? Jurnal Siasat Bisnis, Yogyakarta, v. 21, n. 2, p. 131-141, 2017.
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Revista Brasileira de Inovação